Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Share-based Compensation (2016 - 2026)

Cytosorbents filings provide 15 years of Share-based Compensation readings, the most recent being $886000.0 for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 3.7% to $886000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a 26.49% decrease, with the full-year FY2025 number at $2.8 million, down 26.46% from a year prior.
  • Share-based Compensation hit $886000.0 in Q4 2025 for Cytosorbents, up from $488000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.7 million in Q4 2023 to a low of $488000.0 in Q3 2025.
  • Median Share-based Compensation over the past 5 years was $888500.0 (2024), compared with a mean of $950619.9.
  • Biggest five-year swings in Share-based Compensation: soared 113.59% in 2021 and later plummeted 51.16% in 2022.
  • Cytosorbents' Share-based Compensation stood at $796564.0 in 2021, then increased by 9.22% to $870000.0 in 2022, then skyrocketed by 91.8% to $1.7 million in 2023, then crashed by 44.87% to $920000.0 in 2024, then dropped by 3.7% to $886000.0 in 2025.
  • The last three reported values for Share-based Compensation were $886000.0 (Q4 2025), $488000.0 (Q3 2025), and $571000.0 (Q2 2025) per Business Quant data.